Back to Search Start Over

Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer.

Authors :
Wang Y
Gavan SP
Steinke D
Cheung KL
Chen LC
Source :
Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2022 Mar 01; Vol. 20 (1), pp. 9. Date of Electronic Publication: 2022 Mar 01.
Publication Year :
2022

Abstract

Objective: To appraise the sources of evidence and methods to estimate input parameter values in decision-analytic model-based cost-effectiveness analyses of treatments for primary breast cancer (PBC) in older patients (≥ 70 years old).<br />Methods: Two electronic databases (Ovid Medline, Ovid EMBASE) were searched (inception until 5 September-2021) to identify model-based full economic evaluations of treatments for older women with PBC as part of their base-case target population or age-subgroup analysis. Data sources and methods to estimate four types of input parameters including health-related quality of life (HRQoL); natural history; treatment effect; resource use were extracted and appraised. Quality assessment was completed by reference to the Consolidated Health Economic Evaluation Reporting Standards.<br />Results: Seven model-based economic evaluations were included (older patients as part of their base-case (n = 3) or subgroup (n = 4) analysis). Data from younger patients (< 70 years) were used frequently to estimate input parameters. Different methods were adopted to adjust these estimates for an older population (HRQoL: disutility multipliers, additive utility decrements; Natural history: calibration of absolute values, one-way sensitivity analyses; Treatment effect: observational data analysis, age-specific behavioural parameters, plausible scenario analyses; Resource use: matched control observational data analysis, age-dependent follow-up costs).<br />Conclusion: Improving estimated input parameters for older PBC patients will improve estimates of cost-effectiveness, decision uncertainty, and the value of further research. The methods reported in this review can inform future cost-effectiveness analyses to overcome data challenges for this population. A better understanding of the value of treatments for these patients will improve population health outcomes, clinical decision-making, and resource allocation decisions.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1478-7547
Volume :
20
Issue :
1
Database :
MEDLINE
Journal :
Cost effectiveness and resource allocation : C/E
Publication Type :
Academic Journal
Accession number :
35232445
Full Text :
https://doi.org/10.1186/s12962-022-00342-7